Biography
- Division:
- Division of Basic and Integrative Biological Sciences – DBIB
- Review Branch:
- Molecular and Cellular Sciences and Technologies – MCST
Dr. Khalida Shamim earned her Ph.D. in synthetic organic chemistry from Indiana University, Bloomington, where she focused on the total synthesis of natural products and published her research on stemona alkaloids as well as the quinone methide macrolide, kendomycin. She subsequently joined GlaxoSmithKline as a principal scientist and concentrated her efforts on developing HIV integrase inhibitors. Before her role at CSR, she served as a staff scientist at the National Center for Advancing Translational Sciences (NCATS). In that position, she initially concentrated on rare and neglected diseases, aiming to identify small molecule inhibitors for abnormal ALK2/BMP signaling related to the rare genetic disorder FOP. Later, she shifted her focus to addressing addiction in opioid use disorder, working on discovering novel therapeutics for D3 antagonism. In her latest position at NCATS, she managed a medicinal chemistry team focused on discovering new small molecule inhibitors for viruses of pandemic potential under the Antiviral Program for Pandemics (APP) initiative.
